U.S. markets close in 6 hours 18 minutes

Vericel Corporation (VCEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
16.81-0.39 (-2.24%)
As of 9:42AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close17.19
Open17.10
Bid16.80 x 900
Ask16.87 x 900
Day's Range16.81 - 17.20
52 Week Range6.78 - 19.77
Volume9,466
Avg. Volume637,425
Market Cap758.084M
Beta (5Y Monthly)2.96
PE Ratio (TTM)N/A
EPS (TTM)-0.26
Earnings DateAug 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.40
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Vericel to Report Second-Quarter 2020 Financial Results on August 5, 2020

    CAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its second-quarter 2020 financial results and business highlights.     What: Vericel Corporation Second-Quarter 2020 Earnings Call  When: Wednesday, August 5, 2020 at 8:30am (EDT) Where: http://investors.vcel.com/events-presentations How: The conference call will be available live in the Investors section of the Vericel website at http://investors.vcel.com/events-presentations.  Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary.  Presentation slides for the conference call will be available on the webcast and in the Investor Relations section of the Vericel website.     To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation second-quarter 2020 earnings call.  If calling from outside the U.S., please use the international phone number (253) 237-1173.If you are unable to participate in the live call, the webcast will be available at http://investors.vcel.com/events-presentations until August 5, 2021.  A replay of the call will also be available until 11:00am (EDT) on August 12, 2020 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406.  The conference ID is 5851304.About Vericel CorporationVericel is a leader in advanced therapies for the sports medicine and severe burn care markets.  The company markets two cell therapy products in the United States.  MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults.  Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area.  The company also holds an exclusive license for North American commercial rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns.  For more information, please visit the company's website at www.vcel.com.Epicel® and MACI® are registered trademarks of Vericel Corporation.  NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation.  © 2020 Vericel Corporation.  All rights reserved.Investor Contact: Lee Stern Solebury Trout lstern@troutgroup.com +1 646-378-2922

  • Do Options Traders Know Something About Vericel (VCEL) Stock We Don't?
    Zacks

    Do Options Traders Know Something About Vericel (VCEL) Stock We Don't?

    Investors need to pay close attention to Vericel (VCEL) stock based on the movements in the options market lately.

  • GlobeNewswire

    Vericel Announces Preliminary Second Quarter 2020 Financial Results and Provides Business Updates

    CAMBRIDGE, Mass., July 09, 2020 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced.